Supernus Pharmaceuticals (NASDAQ:SUPN) Sets New 52-Week Low – Here’s Why

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) shares reached a new 52-week low on Tuesday . The stock traded as low as $42.39 and last traded at $42.42, with a volume of 129584 shares traded. The stock had previously closed at $43.53.

Analysts Set New Price Targets

SUPN has been the subject of a number of analyst reports. Weiss Ratings restated a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a research note on Wednesday, June 24th. Zacks Research cut Supernus Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Friday, September 4th. Wall Street Zen downgraded shares of Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, August 8th. Finally, Cantor Fitzgerald upped their target price on shares of Supernus Pharmaceuticals from $63.00 to $67.00 and gave the company an “overweight” rating in a research note on Thursday, July 9th. Four analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $62.83.

Supernus Pharmaceuticals Price Performance

The firm has a 50 day simple moving average of $46.44 and a 200-day simple moving average of $48.22. The stock has a market capitalization of $2.44 billion, a price-to-earnings ratio of -21.87, a price-to-earnings-growth ratio of 0.78 and a beta of 0.56.

Supernus Pharmaceuticals (NASDAQ:SUPN) last posted its earnings results on Monday, August 3rd. The specialty pharmaceutical company reported ($1.01) earnings per share for the quarter, missing the consensus estimate of $0.42 by ($1.43). Supernus Pharmaceuticals had a positive return on equity of 11.13% and a negative net margin of 13.23%.The firm had revenue of $219.06 million during the quarter, compared to the consensus estimate of $205.31 million. During the same period in the previous year, the company posted $0.40 EPS. The firm’s revenue for the quarter was up 32.4% compared to the same quarter last year. On average, sell-side analysts forecast that Supernus Pharmaceuticals, Inc. will post 1.97 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the company. BlackRock Inc. bought a new stake in Supernus Pharmaceuticals during the 2nd quarter worth about $434,871,000. California State Teachers Retirement System raised its stake in shares of Supernus Pharmaceuticals by 4,105.8% in the second quarter. California State Teachers Retirement System now owns 2,846,738 shares of the specialty pharmaceutical company’s stock worth $132,402,000 after acquiring an additional 2,779,052 shares during the last quarter. Rubric Capital Management LP bought a new position in shares of Supernus Pharmaceuticals in the second quarter worth about $21,908,000. Bank of America Corp DE bought a new stake in shares of Supernus Pharmaceuticals during the second quarter valued at approximately $28,887,000. Finally, Assenagon Asset Management S.A. bought a new stake in shares of Supernus Pharmaceuticals during the first quarter valued at approximately $27,428,000.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained?release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended?release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended?release capsules), approved for the treatment of attention?deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.